RE:Levesque, hitting his stride with that presentation It's good they haven't shifted the messaging on NASH now compared to before the financing. The brief quiet period looks more like a positive attempt to promote oncology rather than bury NASH. There's no hesitancy in talking about Ph3 still.
I do think some of what he says about NASH sounds like it's anticipating pushback (eg non-hiv versus hiv) and in my opinion likely reflects the pushback they've been getting for 12-18 months, nothing we haven't discussed already though. How do people understand the language around the EMA? It sounds to me like this will be an FDA focused trial and what they want to do is ensure there will be something in it for the EMA at the end. "Aligned" with the EMA isn't quiet EMA on board. But maybe this is just because they have the FDA letter but are showing some caution about putting words in the EMA's mouth ahead of a decision by them. No attempt to explain that ongoing uncertainty.
No teasers for AACR!
Wino115 wrote: I have to say, he keeps improving as both a presenter and using the strategically placed words that knowlegible investors are used to to make it much more convincing. For us, not much new, but for someone looking the first time, I do think you now would dig deeper -- the pitch does pull you in thinking there's a real solid investment opportunity to at least check out, and that's all you can ask for is for someone to dig, then buy. Well done Paul & Leah.
- Excellent time management to get key points in.
- Explained slides, data support, hit key points, moved on.
- Summarized the key elements in each drug area nicely at end.
I really like how he very clearly discussed both NASH and cancer, was clearest I've heard yet on why the HIV trial and other obese GHRH trials in non-HIV led them to the KOL conclusion it works. Why more time and F2/F3 only will help with endpoint. He used the strategy of making your strong general statement and pointing out exactly what the data and charts are showing to back that up. I've always wanted to see that because they used to throw open the page with all sorts of charts and not really go through what they mean, or jump around from top left to borrom right to bottom left. Now they have a methodical pattern to say their point, show the "picture" of that point and move to the next point.
Very well done on both of those and I think the way they now talk about it is much more convincing. He also spent enough time on the NASH competitive slide to get in to some comparisons that were very well done and made it clear they got theses numbers on a much less healthy functioning liver given ART, etc. .. and he made that point strongly. Also pushed the point that they are safe in much more strongly worded way this time. Wish he had thrown in the market cap range of all those companies -- just say they're worth $200-$1.7bil and we're right there with them but know we are safe. Others will put 2+2 together.
Not sure what will come of this given Wainwrights size and impact, but I think they are getting much more comfortable "pitching" and the confidence they have is creating confidence in what they say, which they need to do given they are unknown still.